NeuBase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

NeuBase Therapeutics

13/05/2022 24:24

* NeuBase Therapeutics Inc  NBSE.OQ  reported a quarterly
adjusted
loss of 30 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 23 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * NeuBase Therapeutics Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * NeuBase Therapeutics Inc shares had fallen by 52.1% this
quarter and lost 68.0% so far this year.
    * The company reported a quarterly loss of $9.92 million.
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 11:23 p.m.  ​All
figures in US dollars unless otherwise stated